pe labeled anti cd25  (BioLegend)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    PE anti rat CD25
    Description:
    PE anti rat CD25 OX 39 Isotype Mouse IgG1 κ Reactivity Rat Apps FC Size 50 μg
    Catalog Number:
    202105
    Price:
    115
    Category:
    Rat Immunology
    Source:
    Mouse
    Applications:
    FC
    Conjugate:
    PE
    Immunogen:
    Rat T cell blasts from mixed lymphocyte reactions
    Size:
    50 μg
    Quantity:
    1
    Preparation:
    The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions The solution is free of unconjugated PE and unconjugated antibody
    Buy from Supplier


    Structured Review

    BioLegend pe labeled anti cd25
    PE anti rat CD25
    PE anti rat CD25 OX 39 Isotype Mouse IgG1 κ Reactivity Rat Apps FC Size 50 μg
    https://www.bioz.com/result/pe labeled anti cd25/product/BioLegend
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pe labeled anti cd25 - by Bioz Stars, 2021-09
    99/100 stars

    Images

    1) Product Images from "Human Natural Killer Cell Maturation Defect Supports In Vivo CD56bright to CD56dim Lineage Development"

    Article Title: Human Natural Killer Cell Maturation Defect Supports In Vivo CD56bright to CD56dim Lineage Development

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0051677

    Lung infection and analysis of blood mononuclear cells. A ) CT scan of the lungs of the patient, showing an area of consolidation of 43×60 mm in right lower lobe parenchyma (indicated by arrows). B ) Lung biopsy (sliced in two pieces) with visible cavitated lesions with mucoid material. C ) Hematoxylin/eosin staining of the lung biopsy showing the infiltration of inflammatory cells with predominance of histiocytes and multinucleated giant cells containing PAS-positive spherical bodies of 5 to 10 μm in diameter (indicated by arrows). The morphological characteristics of these PAS-positive spherical bodies are compatible with Cryptococcus neoformans infection. D ) Absolute numbers of total NK cells, CD3 − CD56 dim cells and CD3 − CD56 bright cells in blood of 6 healthy normal donors (N) and in blood from two draws from different dates (indicated in parentheses) from the patient (P). E ) PBMCs from 9 different normal donors (N) and from different blood draws from different dates (indicated in parentheses) from the patient (P) were stained with anti-CD3 and anti-CD56 mAbs, and the percentage of NK cells (CD3 − CD56 + cells), CD3 − CD56 dim and CD3 − CD56 bright cells within the whole mononuclear cell population (PBMCs) were calculated and depicted as dot plots. Also, the relative abundance of CD3 − CD56 bright and CD3 − CD56 dim cells was calculated and depicted (CD3 − CD56 bright are shown in black bars; CD3 − CD56 dim cells are shown in white bars). Each sample of the patient was tested at least twice, and individual values obtained are shown as a dot in the graphs. Interquartile ranges (IQR) are indicated in the graphs of panels D and E. F ) Representative dot plots of lymphoid cells gated according to their FSC and SSC parameters. The numbers in each region correspond to the percentage of CD3 − CD56 dim and CD3 − CD56 bright cells within the lymphoid population (gated according to their FSC and SSC parameters). G ) Representative dot plots to show the percentage of CD3 − CD56 − CD16 + NK cells within the CD3 − lymphoid cell population in a healthy normal control (N) and in one sample of the patient (P). The numbers in each quadrant correspond to the percentage of CD16 + CD56 − , CD16 + CD56 dim and CD16 − CD56 bright NK cells. Right graph: data from 3 healthy normal controls and 3 blood samples from different dates from the patient (P). Percentages depicted correspond to the percentage of CD3 − CD56 − CD16 + cells within the total NK cell population (CD16 + CD56 − + CD16 + CD56 dim + CD16 − CD56 bright cells). H ) PBMCs from normal donors (N) and from the patient (P) were stained with anti-CD3, anti-CD14 and anti-HLA class I mAbs to assess HLA class I expression (continuous line) on T cells (CD3 + cells) and monocytes (CD14 + cells). Data presented correspond to representative histograms. Dashed lines: IC mAb. The numbers inserted in the graphs correspond to the MFI. I ) PBMCs from normal donors (N) and from the patient (P) were stained with anti-CD4, anti-CD25 and anti-Foxp3 to assess the percentage of Tregs. The dot plots correspond to Foxp3 vs . CD25 in CD4 + cells gated from the FSC vs. SSC plots. The percentages in each quadrant are shown. The right graph shows the percentage of Tregs in PBMCs from 6 healthy normal controls and in two blood samples from different dates (indicated in parentheses) from the patient (P). One representative experiment from 3 independent analyses is shown in C and D. PBMCs from blood samples obtained in February 2011 were used for panels F, H and I.
    Figure Legend Snippet: Lung infection and analysis of blood mononuclear cells. A ) CT scan of the lungs of the patient, showing an area of consolidation of 43×60 mm in right lower lobe parenchyma (indicated by arrows). B ) Lung biopsy (sliced in two pieces) with visible cavitated lesions with mucoid material. C ) Hematoxylin/eosin staining of the lung biopsy showing the infiltration of inflammatory cells with predominance of histiocytes and multinucleated giant cells containing PAS-positive spherical bodies of 5 to 10 μm in diameter (indicated by arrows). The morphological characteristics of these PAS-positive spherical bodies are compatible with Cryptococcus neoformans infection. D ) Absolute numbers of total NK cells, CD3 − CD56 dim cells and CD3 − CD56 bright cells in blood of 6 healthy normal donors (N) and in blood from two draws from different dates (indicated in parentheses) from the patient (P). E ) PBMCs from 9 different normal donors (N) and from different blood draws from different dates (indicated in parentheses) from the patient (P) were stained with anti-CD3 and anti-CD56 mAbs, and the percentage of NK cells (CD3 − CD56 + cells), CD3 − CD56 dim and CD3 − CD56 bright cells within the whole mononuclear cell population (PBMCs) were calculated and depicted as dot plots. Also, the relative abundance of CD3 − CD56 bright and CD3 − CD56 dim cells was calculated and depicted (CD3 − CD56 bright are shown in black bars; CD3 − CD56 dim cells are shown in white bars). Each sample of the patient was tested at least twice, and individual values obtained are shown as a dot in the graphs. Interquartile ranges (IQR) are indicated in the graphs of panels D and E. F ) Representative dot plots of lymphoid cells gated according to their FSC and SSC parameters. The numbers in each region correspond to the percentage of CD3 − CD56 dim and CD3 − CD56 bright cells within the lymphoid population (gated according to their FSC and SSC parameters). G ) Representative dot plots to show the percentage of CD3 − CD56 − CD16 + NK cells within the CD3 − lymphoid cell population in a healthy normal control (N) and in one sample of the patient (P). The numbers in each quadrant correspond to the percentage of CD16 + CD56 − , CD16 + CD56 dim and CD16 − CD56 bright NK cells. Right graph: data from 3 healthy normal controls and 3 blood samples from different dates from the patient (P). Percentages depicted correspond to the percentage of CD3 − CD56 − CD16 + cells within the total NK cell population (CD16 + CD56 − + CD16 + CD56 dim + CD16 − CD56 bright cells). H ) PBMCs from normal donors (N) and from the patient (P) were stained with anti-CD3, anti-CD14 and anti-HLA class I mAbs to assess HLA class I expression (continuous line) on T cells (CD3 + cells) and monocytes (CD14 + cells). Data presented correspond to representative histograms. Dashed lines: IC mAb. The numbers inserted in the graphs correspond to the MFI. I ) PBMCs from normal donors (N) and from the patient (P) were stained with anti-CD4, anti-CD25 and anti-Foxp3 to assess the percentage of Tregs. The dot plots correspond to Foxp3 vs . CD25 in CD4 + cells gated from the FSC vs. SSC plots. The percentages in each quadrant are shown. The right graph shows the percentage of Tregs in PBMCs from 6 healthy normal controls and in two blood samples from different dates (indicated in parentheses) from the patient (P). One representative experiment from 3 independent analyses is shown in C and D. PBMCs from blood samples obtained in February 2011 were used for panels F, H and I.

    Techniques Used: Infection, Computed Tomography, Staining, Expressing

    2) Product Images from "IMMUNE DYSREGULATION BY THE RHEUMATOID ARTHRITIS SHARED EPITOPE 1"

    Article Title: IMMUNE DYSREGULATION BY THE RHEUMATOID ARTHRITIS SHARED EPITOPE 1

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    doi: 10.4049/jimmunol.0904002

    The SE facilitates Th17 differentiation DBA/1 bone marrow-derived CD11c + DCs were cultured overnight in the presence or absence of (A) SE ligand 65–79*0401 or SE-negative control 65–79*0402, or (B) SE-positive T-DRB1*0401 tetramers, versus SE-negative T-DRB1*0301, or T-DRB1*1501 tetramers. Syngeneic splenic CD4 + CD25 − CD62L + CD44 − naïve T cells plus a Th17-differentiation cytokine/antibody cocktail were then added to the culture and incubated for 6 days. Intracellular IL17A was determined by flow cytometry. On the left: a representative experiment, one of three repetitions, showing percentages of CD4 + IL17A + cells as dot plots. On the right: bar graphs show results presented as mean percentage ± SD of replicate samples. *, p
    Figure Legend Snippet: The SE facilitates Th17 differentiation DBA/1 bone marrow-derived CD11c + DCs were cultured overnight in the presence or absence of (A) SE ligand 65–79*0401 or SE-negative control 65–79*0402, or (B) SE-positive T-DRB1*0401 tetramers, versus SE-negative T-DRB1*0301, or T-DRB1*1501 tetramers. Syngeneic splenic CD4 + CD25 − CD62L + CD44 − naïve T cells plus a Th17-differentiation cytokine/antibody cocktail were then added to the culture and incubated for 6 days. Intracellular IL17A was determined by flow cytometry. On the left: a representative experiment, one of three repetitions, showing percentages of CD4 + IL17A + cells as dot plots. On the right: bar graphs show results presented as mean percentage ± SD of replicate samples. *, p

    Techniques Used: Derivative Assay, Cell Culture, Negative Control, Incubation, Flow Cytometry, Cytometry

    The SE inhibits Treg generation (A) DBA/1 bone marrow-derived CD11c + DCs were cultured overnight with 50 µg/ml SE ligand 65–79*0401 or SE-negative control 65–79*0402, or medium. Syngeneic splenic CD4 + T cells were then added to the culture, and incubated with anti-CD3 and TGF-β for 5 days. On the left, flow cytometry dot plots showing percentages of CD25 + Foxp3 + cells obtained from gated CD4 + T cells in each treatment. Each plot is representative of three experiments. On the right, bar graphs present results as mean percentage ± SD of replicate samples. *, p
    Figure Legend Snippet: The SE inhibits Treg generation (A) DBA/1 bone marrow-derived CD11c + DCs were cultured overnight with 50 µg/ml SE ligand 65–79*0401 or SE-negative control 65–79*0402, or medium. Syngeneic splenic CD4 + T cells were then added to the culture, and incubated with anti-CD3 and TGF-β for 5 days. On the left, flow cytometry dot plots showing percentages of CD25 + Foxp3 + cells obtained from gated CD4 + T cells in each treatment. Each plot is representative of three experiments. On the right, bar graphs present results as mean percentage ± SD of replicate samples. *, p

    Techniques Used: Derivative Assay, Cell Culture, Negative Control, Incubation, Flow Cytometry, Cytometry

    Related Articles

    Staining:

    Article Title: LRRC4 functions as a neuron-protective role in experimental autoimmune encephalomyelitis
    Article Snippet: .. For detection of Treg cells, the cells were stained with PE-conjugated anti-CD25 and Alexa Fluor 647-conjugated anti-Foxp3 (BioLegend). ..

    Article Title: Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing, et al. Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing
    Article Snippet: .. 2.9 FACS analysis Pre‐ or post‐QQc cells in EDTA‐PBS containing 2% FBS (FACS buffer) were treated with FcR blocking reagent (Miltenyi, Auburn, California) at 4°C for 30 minutes, and then stained with the specific antibodies PE/Cy7‐labeled anti‐CD31 (clone: WM59, BioLegend, San Diego, California), PE‐labeled anti‐CD34 (clone: 581, BioLegend), APC‐labeled anti‐CD184 (CXCR4, clone: 12G5, BD Bioscience, San Jose, California), APC‐labeled anti‐CD133 (clone: AC133, Miltenyi), Alexa Fluor‐700‐labeled anti‐CD3+ (clone: UCHT1, BioLegend), APC/Cy7‐labeled anti‐CD14 (clone: HCD14, BioLegend), PE/Cy7‐labeled anti‐CD206 (MMR, clone: 15‐2, BioLegend), PerCP/Cy5.5‐labeled anti‐CCR2 (CD192, clone: K036C2, BioLegend), BV421‐labeled anti‐CD127 (clone: A019D5, BioLegend), BV421‐labeled anti‐CD8 (clone: RPA‐T8, BioLegend), FITC‐labeled anti‐CD4 (clone: RPA‐T4, BioLegend), PE‐labeled anti‐CD25 (Clone: M‐A251, BioLegend), or proper isotype controls for each color at 4°C for 30 minutes. ..

    Article Title: Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy
    Article Snippet: .. For the analysis of T cell subpopulations, cells were stained with the following antibody cocktails: Alexa Fluor® 700-conjugated antibody to CD45 (Clone: 30-F11, dilution: 1:200), FITC-conjugated antibody to CD3 (Clone: 17A2, dilution: 1:400), BV650-conjugated antibody to CD8 (Clone: 53-6.7, dilution: 1:200), PE/Dazzle 594-conjugated antibody to CD4 (Clone: GK1.5, dilution: 1:200), and PE-conjugated antibody to CD25 (Clone: 3C7, dilution: 1:100). ..

    FACS:

    Article Title: Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing, et al. Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing
    Article Snippet: .. 2.9 FACS analysis Pre‐ or post‐QQc cells in EDTA‐PBS containing 2% FBS (FACS buffer) were treated with FcR blocking reagent (Miltenyi, Auburn, California) at 4°C for 30 minutes, and then stained with the specific antibodies PE/Cy7‐labeled anti‐CD31 (clone: WM59, BioLegend, San Diego, California), PE‐labeled anti‐CD34 (clone: 581, BioLegend), APC‐labeled anti‐CD184 (CXCR4, clone: 12G5, BD Bioscience, San Jose, California), APC‐labeled anti‐CD133 (clone: AC133, Miltenyi), Alexa Fluor‐700‐labeled anti‐CD3+ (clone: UCHT1, BioLegend), APC/Cy7‐labeled anti‐CD14 (clone: HCD14, BioLegend), PE/Cy7‐labeled anti‐CD206 (MMR, clone: 15‐2, BioLegend), PerCP/Cy5.5‐labeled anti‐CCR2 (CD192, clone: K036C2, BioLegend), BV421‐labeled anti‐CD127 (clone: A019D5, BioLegend), BV421‐labeled anti‐CD8 (clone: RPA‐T8, BioLegend), FITC‐labeled anti‐CD4 (clone: RPA‐T4, BioLegend), PE‐labeled anti‐CD25 (Clone: M‐A251, BioLegend), or proper isotype controls for each color at 4°C for 30 minutes. ..

    Blocking Assay:

    Article Title: Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing, et al. Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing
    Article Snippet: .. 2.9 FACS analysis Pre‐ or post‐QQc cells in EDTA‐PBS containing 2% FBS (FACS buffer) were treated with FcR blocking reagent (Miltenyi, Auburn, California) at 4°C for 30 minutes, and then stained with the specific antibodies PE/Cy7‐labeled anti‐CD31 (clone: WM59, BioLegend, San Diego, California), PE‐labeled anti‐CD34 (clone: 581, BioLegend), APC‐labeled anti‐CD184 (CXCR4, clone: 12G5, BD Bioscience, San Jose, California), APC‐labeled anti‐CD133 (clone: AC133, Miltenyi), Alexa Fluor‐700‐labeled anti‐CD3+ (clone: UCHT1, BioLegend), APC/Cy7‐labeled anti‐CD14 (clone: HCD14, BioLegend), PE/Cy7‐labeled anti‐CD206 (MMR, clone: 15‐2, BioLegend), PerCP/Cy5.5‐labeled anti‐CCR2 (CD192, clone: K036C2, BioLegend), BV421‐labeled anti‐CD127 (clone: A019D5, BioLegend), BV421‐labeled anti‐CD8 (clone: RPA‐T8, BioLegend), FITC‐labeled anti‐CD4 (clone: RPA‐T4, BioLegend), PE‐labeled anti‐CD25 (Clone: M‐A251, BioLegend), or proper isotype controls for each color at 4°C for 30 minutes. ..

    Recombinase Polymerase Amplification:

    Article Title: Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing, et al. Ex vivo conditioning of peripheral blood mononuclear cells of diabetic patients promotes vasculogenic wound healing
    Article Snippet: .. 2.9 FACS analysis Pre‐ or post‐QQc cells in EDTA‐PBS containing 2% FBS (FACS buffer) were treated with FcR blocking reagent (Miltenyi, Auburn, California) at 4°C for 30 minutes, and then stained with the specific antibodies PE/Cy7‐labeled anti‐CD31 (clone: WM59, BioLegend, San Diego, California), PE‐labeled anti‐CD34 (clone: 581, BioLegend), APC‐labeled anti‐CD184 (CXCR4, clone: 12G5, BD Bioscience, San Jose, California), APC‐labeled anti‐CD133 (clone: AC133, Miltenyi), Alexa Fluor‐700‐labeled anti‐CD3+ (clone: UCHT1, BioLegend), APC/Cy7‐labeled anti‐CD14 (clone: HCD14, BioLegend), PE/Cy7‐labeled anti‐CD206 (MMR, clone: 15‐2, BioLegend), PerCP/Cy5.5‐labeled anti‐CCR2 (CD192, clone: K036C2, BioLegend), BV421‐labeled anti‐CD127 (clone: A019D5, BioLegend), BV421‐labeled anti‐CD8 (clone: RPA‐T8, BioLegend), FITC‐labeled anti‐CD4 (clone: RPA‐T4, BioLegend), PE‐labeled anti‐CD25 (Clone: M‐A251, BioLegend), or proper isotype controls for each color at 4°C for 30 minutes. ..

    Flow Cytometry:

    Article Title: Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma
    Article Snippet: .. The following flow cytometry panel was used for lymphocytic analysis: Live/Dead eFluor 780, anti-CD45 BV510, anti-CD4 PE-Cy7, anti-CD8–BV605, anti-CD44 Percpcy5.5, anti-Foxp3 eFluor 450, anti-CD19 BV711, anti-CD25 PE, anti–interferon γ (IFNγ) AF 700, anti-TNFα FITC, and anti–granzyme B Alexa Fluor 647. ..

    Labeling:

    Article Title: CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer
    Article Snippet: .. Following directly labeled anti-mouse primary antibodies were used: Anti-CD8a in BUV 805 (clone 53-6.7, rat IgG2a, BD Pharmigen, 1:100), anti-CD11b in BUV 661 (clone M1/70, rat IgG2b, BD Pharmigen, 1:400), anti-CD45.2 in BUV 653 (clone 30-F11, rat IgG2b, BD Pharmigen, 1:400), anti-VISTA in AF488 (clone MH5A, armenian hamster IgG1, BioLegend, 1:100), anti-CD39 in PerCP-eFluor710 (clone 24DMS1, rat IgG2b, ThermoFisher Scientific, 1:100), anti-LAG3 in BV 421 (clone C9B7W, rat IgG1, BioLegend, 1:100), anti-CD44 in BV 570 (clone IM7, rat IgG2b, BioLegend, 1:100), anti-CD73 in BV 605 (clone TY/11.8, rat IgG1, BioLegend, 1:100), anti-CD25 in BV 650 (clone PC61, rat IgG1, BioLegend, 1:100), anti-PD-1 in BV 785 (clone 29F.1A12, rat IgG2a, BioLegend, 1:100), anti-TCRβ in PE-Cy5 (clone H57-597, armenian hamster IgG1, BioLegend, 1:400), anti-KLRG1 in APC-Cy7 (clone 2F1/KLRG1, armenian hamster IgG1, BioLegend, 1:100), anti-TIM3 in AF647, clone B8.2C12, rat IgG1, BioLegend, 1:100), anti-CD103 in Biotin, clone 2E7, armenian hamster IgG1, BioLegend, 1:100), anti-Streptavidin in BUV 395 (BD, 1:200), anti-Ki67 in BV 480 (clone B56, mouse IgG1, BD, 1:100), anti-TNFα in BV711 (clone MP6-XT22, rat IgG1, BioLegend, 1:400), anti-INFγ BUV 737 (clone XMG1.2, rat IgG1, BD, 1:100), anti-CD4 in BUV 496 (clone GK1.5, rat IgG2b, BD, 1:200), anti-FOXP3 in PE (clone FJK-16s, rat IgG2a, ThermoFisher Scientific, 1:200), anti-EOMES in PE-eFluor610 (clone Dan11mag, rat IgG2a, ThermoFisher Scientific, 1:200), anti-T-bet in PE-Cy7 (clone eBio4B10, rat IgG1, ThermoFisher Scientific, 1:100), anti-CTLA4 in APC-AR700 (clone UC10-4F10-11, armenian hamster IgG1, BD, 1:100) and anti-CD24 in FITC (clone M1/69, rat IgG2b, BioLegend, 1:200). ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98
    BioLegend pe anti cd25
    JNK1 −/− Tregs produce more IL-10 and TGF-β and express more LAG-3 than WT Tregs. <t>CD4+CD25+</t> Tregs from WT or JNK1 −/− were stimulated with anti-CD3 (5 μg/ml) or anti-CD3 anti-CD28 (1 μg/ml) as described in the Methods section. After 72 hours, the percentage of ( a ) IL-10 and ( b ) TGF-β producing cells was determined. ( c ) Mean fluorescence intensity (MFI) of LAG-3, CD62L, ICOS, CD25 and TIM-3 expression by WT and JNK1 −/− Tregs. ( d ) A representative flow cytometry figure. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.
    Pe Anti Cd25, supplied by BioLegend, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti cd25/product/BioLegend
    Average 98 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pe anti cd25 - by Bioz Stars, 2021-09
    98/100 stars
      Buy from Supplier

    94
    BioLegend anti cd25 pe
    Co-deletion of Appl1 and Appl2 do not affect T-cell development. WT and Appl DKO mice at 6 weeks of age were sacrificed to collect thymus (A, B) and spleen cells (C, D). Cells were stained with fluorescence-labeled anti-CD4, CD8, CD44, <t>CD25,</t> Thy1 and
    Anti Cd25 Pe, supplied by BioLegend, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd25 pe/product/BioLegend
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd25 pe - by Bioz Stars, 2021-09
    94/100 stars
      Buy from Supplier

    93
    BioLegend pe anti human cd25
    Glyco-engineered anti-human programmed death-ligand 1 (PD-L1) antibody induces increased CD8 T cell activation in presence of cancer cells. The three anti-PD-L1 variants αPDL1 NG (light gray bar), αPDL1 WT (dark gray bar), and αPDL1 GE (black bar) were tested for their effect on T cell activation (donor A) in allogeneic mixed leukocyte reaction (MLRs) in absence or presence of the cancer cell lines HSC-4 (horizontal stripes), ZR-75-1 (plaid), and Ramos (vertical stripes). MLR without addition of test antibody (medium; white bar) served as negative control. The relative frequencies of <t>CD25</t> + in CD8 T cells were plotted. Statistics: mean and SD were plotted in all graphs. Data are representative of two independent experiments. Significance was tested against the medium control without presence of cancer wells (* p
    Pe Anti Human Cd25, supplied by BioLegend, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pe anti human cd25/product/BioLegend
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pe anti human cd25 - by Bioz Stars, 2021-09
    93/100 stars
      Buy from Supplier

    99
    BioLegend anti cd25
    Helios is more closely associated with disease activity than Foxp3 on CD4 + <t>CD25</t> hi T cells in RA patients. (a) The expression of Helios in CD4 + CD25 hi T cells was similar to Foxp3 on RA Tregs ( p > 0.05). (b) The expression of Helios in CD4 + CD25 hi T cells was negatively correlated with DAS28 score (r=−0.3277, p =0.0044) (left), while the expression of Foxp3 was not associated with DAS28 score on these T cells ( p > 0.05) (right). The p value was measured with Mann-Whitney test. Correlation analyses were carried out using Spearman’s rank correlation test. n.s., not significant.
    Anti Cd25, supplied by BioLegend, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd25/product/BioLegend
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd25 - by Bioz Stars, 2021-09
    99/100 stars
      Buy from Supplier

    Image Search Results


    JNK1 −/− Tregs produce more IL-10 and TGF-β and express more LAG-3 than WT Tregs. CD4+CD25+ Tregs from WT or JNK1 −/− were stimulated with anti-CD3 (5 μg/ml) or anti-CD3 anti-CD28 (1 μg/ml) as described in the Methods section. After 72 hours, the percentage of ( a ) IL-10 and ( b ) TGF-β producing cells was determined. ( c ) Mean fluorescence intensity (MFI) of LAG-3, CD62L, ICOS, CD25 and TIM-3 expression by WT and JNK1 −/− Tregs. ( d ) A representative flow cytometry figure. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.

    Journal: Scientific Reports

    Article Title: c-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice

    doi: 10.1038/s41598-018-21477-9

    Figure Lengend Snippet: JNK1 −/− Tregs produce more IL-10 and TGF-β and express more LAG-3 than WT Tregs. CD4+CD25+ Tregs from WT or JNK1 −/− were stimulated with anti-CD3 (5 μg/ml) or anti-CD3 anti-CD28 (1 μg/ml) as described in the Methods section. After 72 hours, the percentage of ( a ) IL-10 and ( b ) TGF-β producing cells was determined. ( c ) Mean fluorescence intensity (MFI) of LAG-3, CD62L, ICOS, CD25 and TIM-3 expression by WT and JNK1 −/− Tregs. ( d ) A representative flow cytometry figure. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.

    Article Snippet: For flow cytometry, we used FITC anti-CD4, APC anti-CD8, FITC anti-IgM, APC anti-CXCR5, PE anti-PD1, FITC anti-CD62L, PE anti-CD25, APC anti-LAG-3, APC anti-TIM-3, PE anti-PD-1 and FITC anti-ICOS, FITC anti-Annexin V and APC anti-FoxP3 antibodies (all from BioLegend).

    Techniques: Fluorescence, Expressing, Flow Cytometry, Cytometry

    JNK1 −/− Tregs are less apoptotic than WT Tregs. a to c. CD4+CD25+ Tregs from WT or JNK1 −/− were stimulated with isotype control antibodies IgG and IgG2 or anti-CD3 (5 μg/ml) and anti-CD28 (1 μg/ml) as described in the Methods section. After six hours, ( a ) the percentage of Annexin V+ cells was determined by flow cytometry. (b) A representative flow cytometry figure. ( c ) The mRNA expression of pro- and anti-apoptotic genes ( Bax, Mcl-1, Bcl-2, Bcl-Xl, TNFRSF10B, Bim, Noxa, Puma, Akt-1 and TNFRSF1A ) was determined by real-time PCR. ( d ) Liver cells from C57BL/6 mice were isolated and cultured with BALB/c mouse pancreatic islets at a ratio of 10000:1 (1 × 10 5 liver cells and 10 islets) in the presence or absence of CFSE-labeled JNK1 or control siRNA-transfected Tregs from WT C57BL/6 mice (1 × 10 4 ). After 72 hours, the percentages of CFSE+ AnnexinV+ cells were measured by flow cytometry. ( e ) A representative flow cytometry figure. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.

    Journal: Scientific Reports

    Article Title: c-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice

    doi: 10.1038/s41598-018-21477-9

    Figure Lengend Snippet: JNK1 −/− Tregs are less apoptotic than WT Tregs. a to c. CD4+CD25+ Tregs from WT or JNK1 −/− were stimulated with isotype control antibodies IgG and IgG2 or anti-CD3 (5 μg/ml) and anti-CD28 (1 μg/ml) as described in the Methods section. After six hours, ( a ) the percentage of Annexin V+ cells was determined by flow cytometry. (b) A representative flow cytometry figure. ( c ) The mRNA expression of pro- and anti-apoptotic genes ( Bax, Mcl-1, Bcl-2, Bcl-Xl, TNFRSF10B, Bim, Noxa, Puma, Akt-1 and TNFRSF1A ) was determined by real-time PCR. ( d ) Liver cells from C57BL/6 mice were isolated and cultured with BALB/c mouse pancreatic islets at a ratio of 10000:1 (1 × 10 5 liver cells and 10 islets) in the presence or absence of CFSE-labeled JNK1 or control siRNA-transfected Tregs from WT C57BL/6 mice (1 × 10 4 ). After 72 hours, the percentages of CFSE+ AnnexinV+ cells were measured by flow cytometry. ( e ) A representative flow cytometry figure. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.

    Article Snippet: For flow cytometry, we used FITC anti-CD4, APC anti-CD8, FITC anti-IgM, APC anti-CXCR5, PE anti-PD1, FITC anti-CD62L, PE anti-CD25, APC anti-LAG-3, APC anti-TIM-3, PE anti-PD-1 and FITC anti-ICOS, FITC anti-Annexin V and APC anti-FoxP3 antibodies (all from BioLegend).

    Techniques: Flow Cytometry, Cytometry, Expressing, Real-time Polymerase Chain Reaction, Mouse Assay, Isolation, Cell Culture, Labeling, Transfection

    JNK1 siRNA enhances WT Treg production of IL-10 and TGF-β. a to c. Liver cells from C57BL/6 mice were isolated and cultured with BALB/c mouse pancreatic islets at a ratio of 10000:1 (1 × 10 5 liver cells and 10 islets) in the presence or absence of freshly isolated CFSE-labeled and JNK1 or control siRNA-transfected Tregs from WT C57BL/6 mice (10 4 ). After 72 hours, the percentage of Annexin V + cells expressing ( a ) IL-10, ( b ) TGF-β, ( c ) IL-17, ( d ) LAG3, CD25, CD62L, ICOS and TIM-3 was measured by flow cytometry. Tregs from WT C57BL/6 mice were isolated and transfected with JNK1 or JNK2 or control siRNA as described in the Methods section. Twelve hours after transfection, the cells were stimulated with anti-CD3 (5 μg/ml) or anti-CD3 and anti-CD28 (1 μg/ml). After 72 hours, real-time PCR analysis was performed to evaluate gene expression. ( e ) IL-10 ( f ) TGF-β and ( g ) Foxp3. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.

    Journal: Scientific Reports

    Article Title: c-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice

    doi: 10.1038/s41598-018-21477-9

    Figure Lengend Snippet: JNK1 siRNA enhances WT Treg production of IL-10 and TGF-β. a to c. Liver cells from C57BL/6 mice were isolated and cultured with BALB/c mouse pancreatic islets at a ratio of 10000:1 (1 × 10 5 liver cells and 10 islets) in the presence or absence of freshly isolated CFSE-labeled and JNK1 or control siRNA-transfected Tregs from WT C57BL/6 mice (10 4 ). After 72 hours, the percentage of Annexin V + cells expressing ( a ) IL-10, ( b ) TGF-β, ( c ) IL-17, ( d ) LAG3, CD25, CD62L, ICOS and TIM-3 was measured by flow cytometry. Tregs from WT C57BL/6 mice were isolated and transfected with JNK1 or JNK2 or control siRNA as described in the Methods section. Twelve hours after transfection, the cells were stimulated with anti-CD3 (5 μg/ml) or anti-CD3 and anti-CD28 (1 μg/ml). After 72 hours, real-time PCR analysis was performed to evaluate gene expression. ( e ) IL-10 ( f ) TGF-β and ( g ) Foxp3. Mean values, p values and SEs are shown. Data presented are representative of three independent experiments.

    Article Snippet: For flow cytometry, we used FITC anti-CD4, APC anti-CD8, FITC anti-IgM, APC anti-CXCR5, PE anti-PD1, FITC anti-CD62L, PE anti-CD25, APC anti-LAG-3, APC anti-TIM-3, PE anti-PD-1 and FITC anti-ICOS, FITC anti-Annexin V and APC anti-FoxP3 antibodies (all from BioLegend).

    Techniques: Mouse Assay, Isolation, Cell Culture, Labeling, Transfection, Expressing, Flow Cytometry, Cytometry, Real-time Polymerase Chain Reaction

    JNK1 defective Tregs prolong islet allograft survival in liver parenchyma of CDM. A single intraperitoneal injection of streptozotocin (STZ) (180 mg/kg body weight) caused C57BL/6 mice to develop diabetes, as measured by random blood sugar levels after one week. Approximately 200 pancreatic islets obtained from BALB/c mice (donor) were cultured in medium for 12 hours and transplanted into the liver parenchyma of CDM (recipient). Some of the islet allograft recipient mice received CD4+CD25+Foxp3+ cells (10 6 ) from WT or JNK −/− mice (both C57BL/6 background) that were isolated and cultured with islets for 12 hours prior to transfer along with islets as mentioned in the Methods section. Blood glucose levels were measured every 72 hours up to 140 days ( a ). Schematic representation of CD4+CD25+Foxp3+ cell-loaded islets. Blood glucose levels above 300 mg/deciliter were considered to indicate diabetes or failed glucose control ( b ). Percent allograft survival. The percent graft survival was calculated using the log-rank test. Kaplan–Meier survival curves of the mice are shown. Data presented are representative of five independent experiments. Five mice per group were used.

    Journal: Scientific Reports

    Article Title: c-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice

    doi: 10.1038/s41598-018-21477-9

    Figure Lengend Snippet: JNK1 defective Tregs prolong islet allograft survival in liver parenchyma of CDM. A single intraperitoneal injection of streptozotocin (STZ) (180 mg/kg body weight) caused C57BL/6 mice to develop diabetes, as measured by random blood sugar levels after one week. Approximately 200 pancreatic islets obtained from BALB/c mice (donor) were cultured in medium for 12 hours and transplanted into the liver parenchyma of CDM (recipient). Some of the islet allograft recipient mice received CD4+CD25+Foxp3+ cells (10 6 ) from WT or JNK −/− mice (both C57BL/6 background) that were isolated and cultured with islets for 12 hours prior to transfer along with islets as mentioned in the Methods section. Blood glucose levels were measured every 72 hours up to 140 days ( a ). Schematic representation of CD4+CD25+Foxp3+ cell-loaded islets. Blood glucose levels above 300 mg/deciliter were considered to indicate diabetes or failed glucose control ( b ). Percent allograft survival. The percent graft survival was calculated using the log-rank test. Kaplan–Meier survival curves of the mice are shown. Data presented are representative of five independent experiments. Five mice per group were used.

    Article Snippet: For flow cytometry, we used FITC anti-CD4, APC anti-CD8, FITC anti-IgM, APC anti-CXCR5, PE anti-PD1, FITC anti-CD62L, PE anti-CD25, APC anti-LAG-3, APC anti-TIM-3, PE anti-PD-1 and FITC anti-ICOS, FITC anti-Annexin V and APC anti-FoxP3 antibodies (all from BioLegend).

    Techniques: Injection, Mouse Assay, Cell Culture, Isolation

    Co-deletion of Appl1 and Appl2 do not affect T-cell development. WT and Appl DKO mice at 6 weeks of age were sacrificed to collect thymus (A, B) and spleen cells (C, D). Cells were stained with fluorescence-labeled anti-CD4, CD8, CD44, CD25, Thy1 and

    Journal: Journal of cellular physiology

    Article Title: Appl1 and Appl2 are Expendable for Mouse Development but are Essential for HGF-induced Akt Activation and Migration in Mouse Embryonic Fibroblasts

    doi: 10.1002/jcp.25211

    Figure Lengend Snippet: Co-deletion of Appl1 and Appl2 do not affect T-cell development. WT and Appl DKO mice at 6 weeks of age were sacrificed to collect thymus (A, B) and spleen cells (C, D). Cells were stained with fluorescence-labeled anti-CD4, CD8, CD44, CD25, Thy1 and

    Article Snippet: Anti-CD4-APC/Cy7, anti-CD8-PE, anti-CD44-APC/Cy7, and anti-CD25-PE were obtained from BioLegend (San Diego, CA).

    Techniques: Mouse Assay, Staining, Fluorescence, Labeling

    Glyco-engineered anti-human programmed death-ligand 1 (PD-L1) antibody induces increased CD8 T cell activation in presence of cancer cells. The three anti-PD-L1 variants αPDL1 NG (light gray bar), αPDL1 WT (dark gray bar), and αPDL1 GE (black bar) were tested for their effect on T cell activation (donor A) in allogeneic mixed leukocyte reaction (MLRs) in absence or presence of the cancer cell lines HSC-4 (horizontal stripes), ZR-75-1 (plaid), and Ramos (vertical stripes). MLR without addition of test antibody (medium; white bar) served as negative control. The relative frequencies of CD25 + in CD8 T cells were plotted. Statistics: mean and SD were plotted in all graphs. Data are representative of two independent experiments. Significance was tested against the medium control without presence of cancer wells (* p

    Journal: Frontiers in Immunology

    Article Title: Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

    doi: 10.3389/fimmu.2018.01614

    Figure Lengend Snippet: Glyco-engineered anti-human programmed death-ligand 1 (PD-L1) antibody induces increased CD8 T cell activation in presence of cancer cells. The three anti-PD-L1 variants αPDL1 NG (light gray bar), αPDL1 WT (dark gray bar), and αPDL1 GE (black bar) were tested for their effect on T cell activation (donor A) in allogeneic mixed leukocyte reaction (MLRs) in absence or presence of the cancer cell lines HSC-4 (horizontal stripes), ZR-75-1 (plaid), and Ramos (vertical stripes). MLR without addition of test antibody (medium; white bar) served as negative control. The relative frequencies of CD25 + in CD8 T cells were plotted. Statistics: mean and SD were plotted in all graphs. Data are representative of two independent experiments. Significance was tested against the medium control without presence of cancer wells (* p

    Article Snippet: Surface staining for flow cytometry was performed with a variety of monoclonal antibodies coupled to fluorophores: αCD3-APC-H7 (clone: SK7, #560176), αCD3-BV711 (clone: UCHT-1, #563724), αCD8-BV605 (clone: SK1, #564115), and αCD8-FITC (clone: RPA-T8, #555366) were purchased from Becton Dickinson Biosciences. αCD3-PerCPVio700 (clone: REA613, #130-109-465) was purchased from Miltenyi Biotec. αCD4-FITC (clone: RPA-T4, #300538), αCD25-PE (clone: BC96, #302606), αCD56-BV711 (clone: 5.1H11, #362542), and αCD137 (4-1BB)-AF647 (clone: 4B4-1, #309824) were purchased from BioLegend.

    Techniques: Activation Assay, Negative Control

    Glyco-engineered anti-human programmed death-ligand 1 (PD-L1) antibody induces strong CD8 T cell activation in a mixed leukocyte reaction. The three anti-PD-L1 variants αPDL1 NG (open circles), αPDL1 WT (gray triangles), and αPDL1 GE (black squares) were tested for their effect on T cell activation in a mixed leukocyte reaction (MLR). The medium control (black crosses) served as a negative control. T cells as responder cells were isolated from a single healthy donor (donor A). Monocyte-derived dendritic cells as stimulator cells were generated from different healthy donors. (A) IL-2 enzyme-linked immunosorbent assays on day 2 of MLR. The determined concentrations of IL-2 in the culture supernatants were plotted. (B) The activation status of CD8 and CD4 T cells in the MLR was determined on day 5 by flow cytometric analysis. The relative frequencies of CD25 + and CD137 + in CD8 and CD4 T cells were plotted. (C) The proliferation of CFSE-labeled CD8 T cells in the MLR was determined on day 5 by CFSE dilution measured by flow cytometric analysis. Representative plots of CD25 expression and CFSE signal intensity of CD8 T cells are shown. Statistics for (A,B) : besides individual data points ( n = 8 for IL-2 secretion, n = 16 for CD25 expression, and n = 7 for CD137), mean and SEM were plotted in all graphs (* p

    Journal: Frontiers in Immunology

    Article Title: Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

    doi: 10.3389/fimmu.2018.01614

    Figure Lengend Snippet: Glyco-engineered anti-human programmed death-ligand 1 (PD-L1) antibody induces strong CD8 T cell activation in a mixed leukocyte reaction. The three anti-PD-L1 variants αPDL1 NG (open circles), αPDL1 WT (gray triangles), and αPDL1 GE (black squares) were tested for their effect on T cell activation in a mixed leukocyte reaction (MLR). The medium control (black crosses) served as a negative control. T cells as responder cells were isolated from a single healthy donor (donor A). Monocyte-derived dendritic cells as stimulator cells were generated from different healthy donors. (A) IL-2 enzyme-linked immunosorbent assays on day 2 of MLR. The determined concentrations of IL-2 in the culture supernatants were plotted. (B) The activation status of CD8 and CD4 T cells in the MLR was determined on day 5 by flow cytometric analysis. The relative frequencies of CD25 + and CD137 + in CD8 and CD4 T cells were plotted. (C) The proliferation of CFSE-labeled CD8 T cells in the MLR was determined on day 5 by CFSE dilution measured by flow cytometric analysis. Representative plots of CD25 expression and CFSE signal intensity of CD8 T cells are shown. Statistics for (A,B) : besides individual data points ( n = 8 for IL-2 secretion, n = 16 for CD25 expression, and n = 7 for CD137), mean and SEM were plotted in all graphs (* p

    Article Snippet: Surface staining for flow cytometry was performed with a variety of monoclonal antibodies coupled to fluorophores: αCD3-APC-H7 (clone: SK7, #560176), αCD3-BV711 (clone: UCHT-1, #563724), αCD8-BV605 (clone: SK1, #564115), and αCD8-FITC (clone: RPA-T8, #555366) were purchased from Becton Dickinson Biosciences. αCD3-PerCPVio700 (clone: REA613, #130-109-465) was purchased from Miltenyi Biotec. αCD4-FITC (clone: RPA-T4, #300538), αCD25-PE (clone: BC96, #302606), αCD56-BV711 (clone: 5.1H11, #362542), and αCD137 (4-1BB)-AF647 (clone: 4B4-1, #309824) were purchased from BioLegend.

    Techniques: Activation Assay, Negative Control, Isolation, Derivative Assay, Generated, Flow Cytometry, Labeling, Expressing

    Helios is more closely associated with disease activity than Foxp3 on CD4 + CD25 hi T cells in RA patients. (a) The expression of Helios in CD4 + CD25 hi T cells was similar to Foxp3 on RA Tregs ( p > 0.05). (b) The expression of Helios in CD4 + CD25 hi T cells was negatively correlated with DAS28 score (r=−0.3277, p =0.0044) (left), while the expression of Foxp3 was not associated with DAS28 score on these T cells ( p > 0.05) (right). The p value was measured with Mann-Whitney test. Correlation analyses were carried out using Spearman’s rank correlation test. n.s., not significant.

    Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

    Article Title: Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4+ Treg Cells in Patients with Rheumatoid Arthritis

    doi: 10.33594/000000080

    Figure Lengend Snippet: Helios is more closely associated with disease activity than Foxp3 on CD4 + CD25 hi T cells in RA patients. (a) The expression of Helios in CD4 + CD25 hi T cells was similar to Foxp3 on RA Tregs ( p > 0.05). (b) The expression of Helios in CD4 + CD25 hi T cells was negatively correlated with DAS28 score (r=−0.3277, p =0.0044) (left), while the expression of Foxp3 was not associated with DAS28 score on these T cells ( p > 0.05) (right). The p value was measured with Mann-Whitney test. Correlation analyses were carried out using Spearman’s rank correlation test. n.s., not significant.

    Article Snippet: Flow cytometry Freshly obtained peripheral blood mononuclear cell (PBMC) were stained with anti-CD4 (-FITC from Biolegend, OKT4, USA), anti-CD25 (-PE from Biolegend, BC96, USA), anti-CD127 (-PECY7 from Biolegend, A019D5, USA), anti-CD226 (-APC from Biolegend, 11A8, USA), anti-TIGIT (-APC from eBioscience, MBSA43, USA).

    Techniques: Activity Assay, Expressing, MANN-WHITNEY

    Frequencies of CD4 + CD25 hi CD127 low/− Tregs in peripheral blood of RA patients with different therapies. Frequencies of Tregs were compared according to whether RA patients were on treatment (a), such as DMARDs (b), Steroids (c) or TNF-α inhibitors (d) ( p > 0.05). The p value was measured with Mann-Whitney test. n.s., not significant.

    Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

    Article Title: Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4+ Treg Cells in Patients with Rheumatoid Arthritis

    doi: 10.33594/000000080

    Figure Lengend Snippet: Frequencies of CD4 + CD25 hi CD127 low/− Tregs in peripheral blood of RA patients with different therapies. Frequencies of Tregs were compared according to whether RA patients were on treatment (a), such as DMARDs (b), Steroids (c) or TNF-α inhibitors (d) ( p > 0.05). The p value was measured with Mann-Whitney test. n.s., not significant.

    Article Snippet: Flow cytometry Freshly obtained peripheral blood mononuclear cell (PBMC) were stained with anti-CD4 (-FITC from Biolegend, OKT4, USA), anti-CD25 (-PE from Biolegend, BC96, USA), anti-CD127 (-PECY7 from Biolegend, A019D5, USA), anti-CD226 (-APC from Biolegend, 11A8, USA), anti-TIGIT (-APC from eBioscience, MBSA43, USA).

    Techniques: MANN-WHITNEY

    Frequencies of CD4 + CD25 hi CD127 low/− Treg in peripheral blood of RA patients and healthy controls. (a) CD25 + CD127 low/− Treg cells were gated within the CD4 + T cell population in peripheral blood mononuclear cells (PBMCs) from RA patients. Almost all CD4 + CD25 hi CD127 low/− cells are Foxp3 + cells. (b) Frequencies of CD4 + CD25 hi CD127 low/− Tregs were compared between healthy controls (3.17±1.49%) and RA patients (3.77±1.98%) ( p > 0.05). (c) Frequencies of Tregs were compared between healthy controls and RA patients with different levels of disease activity ( p > 0.05). The p value was measured with Mann-Whitney test. n.s., not significant.

    Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

    Article Title: Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4+ Treg Cells in Patients with Rheumatoid Arthritis

    doi: 10.33594/000000080

    Figure Lengend Snippet: Frequencies of CD4 + CD25 hi CD127 low/− Treg in peripheral blood of RA patients and healthy controls. (a) CD25 + CD127 low/− Treg cells were gated within the CD4 + T cell population in peripheral blood mononuclear cells (PBMCs) from RA patients. Almost all CD4 + CD25 hi CD127 low/− cells are Foxp3 + cells. (b) Frequencies of CD4 + CD25 hi CD127 low/− Tregs were compared between healthy controls (3.17±1.49%) and RA patients (3.77±1.98%) ( p > 0.05). (c) Frequencies of Tregs were compared between healthy controls and RA patients with different levels of disease activity ( p > 0.05). The p value was measured with Mann-Whitney test. n.s., not significant.

    Article Snippet: Flow cytometry Freshly obtained peripheral blood mononuclear cell (PBMC) were stained with anti-CD4 (-FITC from Biolegend, OKT4, USA), anti-CD25 (-PE from Biolegend, BC96, USA), anti-CD127 (-PECY7 from Biolegend, A019D5, USA), anti-CD226 (-APC from Biolegend, 11A8, USA), anti-TIGIT (-APC from eBioscience, MBSA43, USA).

    Techniques: Activity Assay, MANN-WHITNEY

    TIGIT-expression on Treg cells has no significant suppressive capacity. (a) Expanded human Treg subsets co-cultured with CFSE-labeled CD25 − T cell and OKT3 (30ng/ml) for 72 hours in the presence of irradiated APCs. The CFSE dilution was examined by flow cytometry and data is representative of 4 independent experiments. (b) Statistical summary of 4 RA patients. There were no significant differences in suppressive capacity between TIGIT + Treg and TIGIT − Treg subsets ( p > 0.05).

    Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

    Article Title: Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4+ Treg Cells in Patients with Rheumatoid Arthritis

    doi: 10.33594/000000080

    Figure Lengend Snippet: TIGIT-expression on Treg cells has no significant suppressive capacity. (a) Expanded human Treg subsets co-cultured with CFSE-labeled CD25 − T cell and OKT3 (30ng/ml) for 72 hours in the presence of irradiated APCs. The CFSE dilution was examined by flow cytometry and data is representative of 4 independent experiments. (b) Statistical summary of 4 RA patients. There were no significant differences in suppressive capacity between TIGIT + Treg and TIGIT − Treg subsets ( p > 0.05).

    Article Snippet: Flow cytometry Freshly obtained peripheral blood mononuclear cell (PBMC) were stained with anti-CD4 (-FITC from Biolegend, OKT4, USA), anti-CD25 (-PE from Biolegend, BC96, USA), anti-CD127 (-PECY7 from Biolegend, A019D5, USA), anti-CD226 (-APC from Biolegend, 11A8, USA), anti-TIGIT (-APC from eBioscience, MBSA43, USA).

    Techniques: Expressing, Cell Culture, Labeling, Irradiation, Flow Cytometry, Cytometry